Lesion size, patient age, and current ipsilateral breast cancer are statistically significant predictors of pathologic outcome for nonmasslike enhancement lesions seen on breast MRI, according to a scientific session presented on Sunday at the RSNA 2009 meeting.
Lesion size, patient age, and current ipsilateral breast cancer are statistically significant predictors of pathologic outcome for nonmasslike enhancement lesions seen on breast MRI, according to a scientific session presented on Sunday at the RSNA 2009 meeting.
Nonmasslike enhancement lesions (NMLE) show up regularly on breast MRI, and the current study, by Dr. Eugene Ong, a radiologist in Singapore, validates specific BI-RADS modifiers for the lesions.
In the prospective study of 565 MR-guided breast biopsy cases, 215 cases were reported as NMLE. Of those lesions, 159 were benign and 46 were malignant. Nearly half of the malignant lesions (53.6%) were in situ carcinoma and the rest were invasive. There was no difference in average size of malignant (3 cm) and benign NMLE (2.5 cm). However, the researchers found lesions greater than 4 cm were more likely to be malignant.
Another interesting factor for predictors of outcome was age. The mean patient ages for benign and malignant lesions were 48 years and 55 years, respectively.
Lastly, ipsilateral breast cancer played a role in pathologic outcome. A greater proportion of malignant NMLE was found in patients with ipsilateral breast cancer compared with all other patients, Ong said.
In 35 cases with NMLE ipsilateral to a recent breast cancer, 45% were malignant.
The most common internal enhancement patterns for the lesions were clumped, followed by heterogeneous, which accounted for 80.5% of all NMLE. The positive predictive value was 28% for each.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
Surveillance Breast MRI Associated with Lower Risks of Advanced Second Breast Cancers
January 8th 2025After propensity score matching in a study of over 3,000 women with a personal history of breast cancer, researchers found that surveillance breast MRI facilitated a 59 percent lower risk in advanced presentations of second breast cancers.
Abbreviated MRI for Hepatocellular Carcinoma: What a New Meta-Analysis Reveals
January 6th 2025For hepatocellular carcinoma screening, a 19-study meta-analysis found the abbreviated MRI sequencing protocol of T2-weighted MRI, diffusion-weighted imaging (DWI) and hepatobiliary phase (HBP) imaging offered 88 percent sensitivity and 93 percent specificity.
New CT and MRI Research Shows Link Between LR-M Lesions and Rapid Progression of Early-Stage HCC
January 2nd 2025Seventy percent of LR-M hepatocellular carcinoma (HCC) cases were associated with rapid growth in comparison to 12.5 percent of LR-4 HCCs and 28.5 percent of LR-4 HCCs, according to a new study.